Update, November 3, 2026
Since the October 26 report, Dr. Reddy's has gained 4.98% over five days, closing at INR 1370.0 on November 3, 2026, while the S&P 500 fell 1.88% and the healthcare sector ETF XLV rose 3.38%. The stock's relative strength is notable, with a 16.1% lead over the S&P 500 over 50 days and a 5.5% lead over XLV. A key driver was the October 29 announcement that the USFDA classified the FTO-SEZ Process Unit-02 inspection as Voluntary Action Indicated, a favorable regulatory outcome (NASDAQ Stock Market). Additionally, Jefferies upgraded the stock to Hold with a price target of INR 1,320 on October 25, citing margin strength (Investing.com).
The picture holds. The stock remains above its 40-week average, and the daily trend aligns with the weekly uptrend. The price is now just 0.46% below the 52-week high of 1376.3, with resistance at 1376.3, 1400, and 1450. Support levels are at 1350 (round), 1300, 1252.96 (swing zone), and 1246.52 (200-day SMA). The RSI at 77.26 is elevated, but the trend remains intact. The breakout level is a daily close above 1376.3 on volume above the 20-day average; a stop at 1341.76 would be used. Targets are 1400 (reward-to-risk 0.7) and 1450 (reward-to-risk 2.1). What would change the picture is a weekly close below 1246.52, the 200-day SMA, which has moved up from 1243.48.
Dr. Reddy's Laboratories Limited jumped 7.2% to INR 1,313 in the latest session after second-quarter results showed margins recovering even as revenue slipped. DRREDDY.BO now trades above its 200-day average inside a weekly uptrend. The balance of evidence for the next two to six weeks leans positive, at medium conviction. The catch is that the price already sits on the average analyst target, and the breakout math falls short of 3 to 1.
Why it matters
The company reported Q2 FY27 results on October 23, 2026. Revenue was INR 8,671 crores, down 1.5% from a year earlier but up 7% from the prior quarter, with an EBITDA margin of 20.6% and profit after tax of INR 925 crores, according to Investing.com. North America revenue fell 23% to INR 2,489 crores after the loss of lenalidomide exclusivity. So the headline was a shrinking top line, with the damage concentrated in one product in one region.
The shares reacted to what sat beneath that headline. Revenue came in about 1.5% above the $891.5 million forecast, and gross margin rose to 52.1%, up 562 basis points from the prior quarter, per Investing.com's call summary. The stock rose 7.2% on the day, and volume ran about 214% above its 20-day average. That is a heavy, one-directional repricing, not a drift. It is also 9.2% higher over a month, which means part of the good news was being bought before the numbers arrived. The price is still 4.6% below the 52-week high of INR 1,376.3.
Most of the five-day move belongs to the stock itself. DRREDDY.BO gained 6.6% over five days, while the S&P 500 (SPY) lost 0.4% and the healthcare sector fund XLV gained 1.5%. That leaves the stock 5.1 points ahead of its sector. The earnings explain this. Over 50 days the picture is less flattering: the stock leads SPY by 3.4% but trails XLV by 3.4%, so this rally is a catch-up with a sector that has run ahead of it.
The debate has two sides, and no standalone opinion pieces were available to cite, so both come from the earnings coverage. The positive case rests on emerging markets growing 84% and on management's plan to relaunch semaglutide in November 2026, pending validation, with a target of 6M to 7M devices, as Seeking Alpha reports. The cautious case is that the base business is masking a drag. The Motley Fool's transcript shows North America down 29% in dollar terms to $264 million, with price erosion in Europe on top. On valuation, the Street has little left to add: the mean price target of INR 1,313.16 from 38 analysts matches the INR 1,313 price, the consensus is hold, and targets run from INR 1,024 to INR 1,615.
What the evidence says
The long-term thesis is intact but unspectacular. The price is above its 40-week average and above the 200-day average at INR 1,243.48, and it sits 15.6% above the 52-week low of INR 1,135.65. Yet the six-month change is roughly flat at -0.2%, and the year-to-date gain of 4.7% trails SPY's 11.4% and XLV's 15.8%. This looks like a recovery leg after a long stretch of going nowhere, not yet a new advance.
For the next two to six weeks the balance of evidence leans positive, with medium conviction: 2 of 4 points. The daily trend runs in the same direction as the weekly uptrend, and the 50-day lead over the S&P 500 adds to it. The stock's lag behind XLV over the same 50 days works against it, and that is why the reading stops at medium. History adds only a thin edge. After RSI first rose above 70, shares were higher a month later 58.7% of the time against 61.8% typically, with a median move of 0.92% across 583 cases. After reclaiming the 200-day average, the figures were 59.3% and a median of 1.69% across 91 cases.
The strongest case against is that the news is now in the price. RSI is 70.83, which is overbought. The stock sits exactly on the average analyst target. It has trailed its sector for 50 days, and both historical samples came in slightly below the typical hit rate. A stock that has just gained 7% in a day can easily give some of it back. This does not tip the balance, because the trend structure and the volume behind the move are still intact, but it is the reason conviction is not higher.
Levels that matter
The structure holds above INR 1,300, a round number and the first place a failure would show. A close under it would be the first crack. The trend ends below INR 1,243.48, the 200-day average, which has a swing zone at INR 1,252.96 just above it. Below those sit INR 1,201.6 and the 50-day average at INR 1,194.84.
The breakout level is a daily close above INR 1,345.8 on volume above its 20-day average. From there the first target is the 52-week high of INR 1,376.3, with the INR 1,400 round number beyond it. A stop at INR 1,291.81, which is INR 1,300 less a quarter of ATR, marks where the breakout would be wrong. Against that stop the move to INR 1,376.3 gives a reward-to-risk of 0.6 to 1. The math does not reach 3 to 1. It would take a target well beyond INR 1,400, such as the Street's high of INR 1,615, or a much tighter stop to get there.
What would change the picture
A weekly close below INR 1,243.48, the 200-day average, would end the weekly uptrend and undo the positive reading. The non-price fact that would most likely cause it is a slip in the semaglutide relaunch. If validation delays the November 2026 date, the main new growth driver that justified the earnings reaction would be pushed out while lenalidomide erosion continues.
What to watch
- Next earnings, January 21, 2027: the number that matters is North America revenue, which fell 23% to INR 2,489 crores this quarter. A stable figure would show the lenalidomide drag has been absorbed.
- Semaglutide relaunch: management's November 2026 timing and the 6M to 7M device target are the first checkpoint ahead of the company's own results.
- The sector: XLV fell 1.1% on the day the stock rose 7.2%. If the sector fund, up 6.2% over a month, loses momentum, the stock's recent catch-up gets harder to extend.
- Valuation: the price of INR 1,313 equals the mean target of INR 1,313.16, so further gains need analysts to raise targets above the current consensus.